Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials

Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose

(2011) Sripal Bangalore et al.   CIRCULATION

Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension

(2011) Angela M. Thompson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Irbesartan in Patients with Atrial Fibrillation

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials

(2010) Sébastien Czernichow et al.   JOURNAL OF HYPERTENSION

Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension

(2010) Peter M Rothwell   LANCET

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

(2009) T. Sawada et al.   EUROPEAN HEART JOURNAL

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials

(2009) J. J. Brugts et al.   EUROPEAN HEART JOURNAL

The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League

(2009) Stephan Lüders et al.   JOURNAL OF HYPERTENSION

Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?

(2008) Willem J. Remme et al.   CARDIOVASCULAR DRUGS AND THERAPY

Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial

(2008) Inder S. Anand et al.   Circulation-Heart Failure

Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program

(2008) Peter A. Meredith et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

(2008) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE